[Analysis on Performance and Microbial Community Dynamics of a Strengthen Circulation Anaerobic Reactor Treating Municipal Wastewater].

A strengthen circulation anaerobic reactor (SCAR) treating artificial municipal wastewater was investigated under different volumetric loading rate(VLR) and the reactor performance, characteristics of granular sludge and microbial community structure were also tested in this experiment. The results of the experiment demonstrated that the hydraulic retention time (HRT) of 6h could be regarded as the key parameter dominating the efficient operation of SCAR reactor, in which condition the COD removal efficiency was above 75%. The coenzyme F420and the maximum specific methanogenic activity (SMA) of granular sludge increased with increasing VLR, and the EPS contents, especially TB-EPS in the granule sludge also increased obviously. Consistently, the characteristics of anaerobic granular sludge and the removal efficiency of the reactor were influenced by both sludge loading and HRT. The microbial community structure and its spatial distribution in the reactor were also affected by sludge loading, while the relative abundance of the microbial community with different metabolic characteristics in different spatial positions changed with the adjustment of the sludge loading.

Stability of the recombinant anti­erbB2 scFv­Fc­interleukin­2 fusion protein and its inhibition of HER2­overexpressing tumor cells.

The anti­erbB2 scFv­Fc­IL­2 fusion protein (HFI) is the basis for development of a novel targeted anticancer drug, in particular for the treatment of HER2­positive cancer patients. HFI was fused with the anti­erbB2 antibody and human IL­2 by genetic engineering technology and by antibody targeting characteristics of HFI. IL­2 was recruited to target cells to block HER2 signaling, inhibit or kill tumor cells, improve the immune capacity, reduce the dose of antibody and IL­2 synergy. In order to analyse HFI drug ability, HFI plasmid stability was verified by HFI expression of the trend of volume changes. Additionally, HFI could easily precipitate and had progressive characteristics and thus, the buffer system of the additive phosphate­citric acid buffer, arginine, Triton X­100 or Tween­80, the establishment of a microfiltration, ion exchange, affinity chromatography and gel filtration chromatography­based purification process were explored. HFI samples were obtained according to the requirements of purity, activity and homogeneity. In vivo, HFI significantly delayed HER2 overexpression of non­small cell lung cancer (Calu­3) in human non­small cell lung cancer xenografts in nude mice, and the inhibition rate was more than 60% (P<0.05) in the group treated with 1 mg/kg the HFI dose; HFI significantly inhibited HER2 expression of breast cancer (FVB/neu) transgenic mouse tumor growth in 1 mg/kg of the HFI dose group, and in the following treatment the 400 mm3 tumors disappeared completely. Combined with other HFI test data analysis, HFI not only has good prospects, but also laid the foundation for the development of antibody­cytokine fusion protein­like drugs.